[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:cns-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":21,"states":22},"CNS Lymphoma",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06730542","Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma",[11],"Phase 1","RECRUITING","2026-08-26T02:15:31.806698Z","2026-05-05T02:43:29.171720Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05798897","Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed\u002FRefractory Lymphoma",[11],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:29.017826Z",[],[]]